Medicare Enrolled
Dr. Abdelnaser Elkhalili, MD
Rheumatology · Webster, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Elkhalili from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Elkhalili?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Elkhalili
Dr. Abdelnaser Elkhalili is a rheumatology specialist in Webster, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Elkhalili performed 145,295 Medicare services across 2,117 unique beneficiaries.
Between the years covered by Open Payments, Dr. Elkhalili received a total of $22,484 from 61 pharmaceutical and/or device companies across 1289 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Elkhalili is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 9% volume in TX
$22,484 industry payments
Medicare Practice Summary
Medicare Utilization ↗145,295
Medicare services
Top 9% in TX for rheumatology
2,117
Unique beneficiaries
$20
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,265 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
55,202 | $4 | $15 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
55,060 | $34 | $130 |
| Romosozumab injection (Evenity) for osteoporosis | 16,805 | $8 | $30 |
| Denosumab injection (Prolia/Xgeva) | 5,529 | $18 | $68 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
3,611 | $26 | $140 |
| Hymovis intra-articular injection An injection of Hymovis, a hyaluronan derivative, administered directly into a joint space. |
2,304 | $13 | $50 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,562 | $95 | $386 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
979 | $102 | $394 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
954 | $1 | $3 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
549 | $57 | $219 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
497 | $126 | $541 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
446 | $7 | $33 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
256 | $51 | $193 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
252 | $69 | $272 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
241 | $59 | $266 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
200 | $0 | $2 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
162 | $43 | $171 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
154 | $23 | $85 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
128 | $23 | $87 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
70 | $121 | $503 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
61 | $10 | $43 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
57 | $1 | $3 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
56 | $4 | $18 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
48 | $3 | $12 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
28 | $1 | $6 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
19 | $44 | $186 |
| Shoulder X-ray, 2+ views An X-ray imaging test of the shoulder joint using at least two different angles to visualize the bones and surrounding structures. |
19 | $28 | $105 |
| X-ray of both knees, standing An X-ray image of both knees taken while the patient is standing to assess bone alignment and joint space under weight-bearing conditions. |
18 | $31 | $121 |
| New patient office visit, complex (60-74 min) | 15 | $142 | $664 |
| X-ray of both hips, 2 views An X-ray imaging test that captures two views of both hip joints to evaluate bone structure and alignment. |
13 | $31 | $125 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
41.3% high complexity
56.9% medium
1.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$22,484
Total received (2018-2024)
Avg $3,212/year across 7 years
Top 17% in TX for rheumatology
61
Companies
1,289
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$22,381 (99.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$103 (0.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,211
2023
$3,393
2022
$2,854
2021
$3,182
2020
$3,530
2019
$3,007
2018
$3,306
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$4,205
PFIZER INC.
$1,772
UCB, Inc.
$1,658
ABBVIE INC.
$1,539
Janssen Biotech, Inc.
$1,328
E.R. Squibb & Sons, L.L.C.
$1,089
Novartis Pharmaceuticals Corporation
$883
Mallinckrodt Hospital Products Inc.
$882
AbbVie Inc.
$859
Lilly USA, LLC
$811
GlaxoSmithKline, LLC.
$741
Aurinia Pharma U.S., Inc.
$677
AstraZeneca Pharmaceuticals LP
$657
GENZYME CORPORATION
$591
Genentech USA, Inc.
$584
AbbVie, Inc.
$583
Horizon Therapeutics plc
$534
Radius Health, Inc.
$386
Celgene Corporation
$335
ANI Pharmaceuticals, Inc.
$292
Mallinckrodt LLC
$236
Horizon Pharma plc
$215
Antares Pharma, Inc.
$165
Boehringer Ingelheim Pharmaceuticals, Inc.
$164
Alexion Pharmaceuticals, Inc.
$108
Bioventus LLC
$83
Organon Llc
$77
SANOFI-AVENTIS U.S. LLC
$77
Kiniksa Pharmaceuticals, Ltd.
$75
Mallinckrodt Enterprises LLC
$64
Janssen Pharmaceuticals, Inc
$62
Sobi, Inc
$60
Exeltis, USA Inc.
$53
DePuy Synthes Sales Inc.
$46
MEDEXUS PHARMA, INC.
$38
AVEO Pharmaceuticals, Inc.
$36
Sandoz Inc.
$35
BioDelivery Sciences International, Inc.
$35
Flexion Therapeutics, Inc.
$31
Abbott Laboratories
$29
Assertio Therapeutics, Inc.
$29
Kiniksa Pharmaceuticals International, plc
$28
Myovant Sciences Inc.
$27
Mylan Institutional Inc.
$23
Daiichi Sankyo Inc.
$22
Kyowa Kirin, Inc.
$22
Vertical Pharmaceuticals, LLC
$21
MEDAC PHARMA, INC.
$20
Teva Pharmaceuticals USA, Inc.
$20
FIDIA PHARMA USA INC.
$20
Ultragenyx Pharmaceutical Inc.
$20
SOBI, INC
$17
BeiGene USA, Inc.
$17
Ironwood Pharmaceuticals, Inc
$15
Musculoskeletal Transplant Foundation Inc.
$14
United Therapeutics Corporation
$13
Orthogenrx Inc.
$13
Kowa Pharmaceuticals America, Inc.
$13
Zyla Life Sciences
$12
Takeda Pharmaceuticals U.S.A., Inc.
$11
Iroko Pharmaceuticals, LLC
$11
Top 3 companies account for 34.0% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Arcalyst · BELBUCA · BENLYSTA · BRUKINSA · Bimzelx · CINCH · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUEXIS · DUZALLO · Dexilant · Durolane · ERBITUX · EVENITY · Enbrel · Enhertu · Esbriet · FORTEO · FOTIVDA · GenVisc 850 · Gralise · HADLIMA · HUMIRA · Humira · Hymovis · ILARIS · IMBRUVICA · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · LORZONE · LUPKYNIS · LYRICA · MONOVISC · NONE · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · ORGOVYX · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SEGLENTIS · SIMPONI · SIMPONI ARIA · SKYRIZI · SPRIX · STELARA · STRENSIQ · SYNVISC-ONE · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tavneos · Truxima · Tymlos · ULTOMIRIS · VIVLODEX · VRAYLAR · XARELTO · XELJANZ · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $15 per 100 Medicare services performed
Geographic Context
Rheumatologists within 10 mi
54
Per 100K population
1.1
County median income
$73,104
Nearest hospital
HCA HOUSTON HEALTHCARE CLEAR LAKE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Elkhalili is a mixed practice specialist, with above-average Medicare volume (top 9% in TX), with low-engagement industry engagement in the top 17% of TX peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Elkhalili experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Elkhalili performed 55,202 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Elkhalili receive payments from pharmaceutical companies?
Yes. Dr. Elkhalili received a total of $22,484 from 61 companies across 1,289 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Elkhalili's costs compare to other rheumatologists in Webster?
Dr. Elkhalili's average Medicare payment per service is $20. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Elkhalili) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Webster
Browse rheumatologists in Webster ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in TX
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in TX
Which TX rheumatologists receive the most from drug and device companies.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology